INTRODUCTION {#rjw179s1}
============

Neuroendocrine carcinomas of the urinary bladder are rare. They account for \<1% of bladder malignancies \[[@rjw179C1]\]. The majority of neuroendocrine carcinomas of the urinary bladder are small cell carcinomas. In recent years, a few cases of large cell neuroendocrine carcinomas (LCNEC) have also been reported \[[@rjw179C2]\].

We present a case of LCNEC of the urinary bladder which achieved complete spontaneous remission.

CASE REPORT {#rjw179s2}
===========

Mr U is a 72-year-old male, with a background of clinical T2N0M0 High Grade Urothelial Carcinoma bladder cancer treated with radical radiotherapy with neoadjuvant Cisplatin 2 years previously. He represented with back pain and acute kidney injury.

An US renal tract during this presentation showed a soft tissue mass in the base of the bladder causing bilateral ureteric obstruction. Bilateral nephrostomies were placed and his kidney function improved.

He proceeded to a biopsy of his prostate and bladder. Histology demonstrated neuroendocrine carcinoma with extensive crush artefact, with mainly small cells. His PSA was 5.9 ug/L and Chromogranin A was 214 U/L. CT Staging showed locally advanced malignancy with concern for local involvement of the mid rectum, there was no evidence of metastatic disease.

He subsequently commenced on a combination of androgen deprivation therapy and neoadjuvant chemotherapy (carboplatin/etoposide). After three cycles of chemotherapy, a PET-CT was done which showed no reduction of the large tumour volume and no metastatic disease. The patient was experiencing severe local symptoms and it was elected to go forward with radical pelvic surgery.

He proceeded to a radical cysto-prostatectomy where the tumour was able to be dissected from the rectum. Histology revealed a LCNEC (Fig. [1](#rjw179F1){ref-type="fig"}), positive for neuroendocrine immunohistochemical markers synaptophysin, chromogranin and CD56. The tumour involved the bladder, with invasion through to adipose tissue and posteriorly at perivesical resection margins (pT4a). Obturator and external iliac nodes were involved. In addition, there was a large Gleason score 9 prostatic adenocarcinoma, distinct from the neuroendocrine carcinoma of the bladder and lacking neuroendocrine immune-histochemical positivity. Peritoneal fluid aspirated during the operation was negative for malignancy. Figure 1:LCNEC in the external iliac lymph node. Nuclei are several times the diameter of lymphocytes (lower left), nucleoli are prominent, and chromatin quite coarse. Some nuclear moulding is seen, as in the small cell variant.

Following surgery, the patient made a good recovery, however, represented 3 months later with significant deterioration in functional status, nausea, weight loss and anorexia. A further PET-CT (Fig. [2](#rjw179F2){ref-type="fig"}) demonstrated metastatic disease with the local recurrence of the mass extending into cystectomy bed. Figure 2:CT-PET performed after surgery showing metastatic disease with local recurrence of the mass extending into the cystectomy bed.

The patient declined further intervention and was referred to hospice for end of life cares. Following referral to the Hospice he underwent a steady and gradual improvement in clinical status. He was discharged from hospice after 4 months. He did not undergo any further medical intervention, faith healing or homeopathic remedies. He decided to live life to its fullest and went sailing around the Mediterranean and Pacific Islands. Following his travels he still felt well and a PET-CT was requested (Fig. [3](#rjw179F3){ref-type="fig"}). This revealed complete remission of the disease present on the imaging 12 months prior. The patient remains still disease free on imaging two years following his spontaneous remission (3 years since completion of any chemotherapy and his subsequent surgery). Figure 3:CT-PET done one year from the previous CT-PET. This showed complete remission of disease. No evidence of distant metastatic disease.

DISCUSSION {#rjw179s3}
==========

This case demonstrates a case of prolonged spontaneous remission in a patient with LCNEC in the setting of previous chemo-radiotherapy for transitional cell carcinoma. We are not aware of any cases of spontaneous remission of bladder cancer.

The most common neuroendocrine tumour of the bladder is small cell neuroendocrine carcinoma , followed by carcinoid tumours (typical and atypical), and LCNEC \[[@rjw179C3]\].

Large cell neuroendocrine tumour of the bladder was first described in 1986 \[[@rjw179C4]\] and, until now, 17 cases have been published in the international literature \[[@rjw179C3]\]. Most cases showed mixed histology. The most common histology is mixed with urothelial cancer, followed by adenocarcinoma, squamous cell carcinoma and sarcomatoid urothelial cancer. Only eight cases were of pure LCNEC type were reported.

In our case, our case presumably arose in a background of high-grade urothelial carcinoma, though none was found at the time of biopsy or cysto-prostatectomy.

Differential diagnosis of pure LCNEC includes metastatic LCNEC from pulmonary or gastrointestinal primary sites, local invasion of the bladder by poorly differentiated prostatic carcinoma in male patients, and primary bladder lesions such as large cell lymphomas and high-grade, undifferentiated urothelial carcinomas. These are distinguished mainly by immunohistochemistry.

The large cell variant of neuroendocrine carcinoma is considered closely related to the more common small cell variant, distinguished mainly by large total cell and nuclear size, prominent nucleoli and coarser chromatin. There is some evidence of biological differences in the two variants when occurring in the lung \[[@rjw179C5]\], but too few cases occur in the bladder for comparisons to be made.

We believe that the present case is the 10th reported case of pure LCNEC of urinary bladder proven post-cystectomy \[[@rjw179C2]\]. The previous cases are summarized in Table [1](#rjw179TB1){ref-type="table"}. Table 1Reported cases of 'pure' LCNEC of the urinary bladderSourceAgeSexSurgeryAdjuvant chemotherapy or radiotherapyStatus at last follow-upf/u PeriodHailemariam et al. [@rjw179C6]73MRadical cysto-prostatectomyNot given as immunosuppresedDied2 Months after surgeryLee et al. [@rjw179C7]32MPartial cystectomyChemotherapyAlive with lung and liver mets10 MonthsAlijo et al. [@rjw179C8]40MRadical cysto-prostatectomyChemotherapyAlive13 MonthsAlijo et al. [@rjw179C8]43FRadical cysto-prostatectomyRadiotherapyDied12 MonthsBertaccini et al. [@rjw179C9]37NARadical cysto-prostatectomyChemotherapyAlive22 MonthsLee et al. [@rjw179C10]20MPartial cystectomyChemotherapyAlive with lung, retroperitoneal nodal mets12 MonthsMartin et al. [@rjw179C3]69MRadical cystectomyNilAlive12 MonthsColarossi et al. [@rjw179C11]53FCystectomyChemotherapyDied7 MonthsPusiol et al. [@rjw179C2]68MRadical cysto-prostatectomyRadiotherapy and ChemotherapyAlive with liver and bone mets16 Months

Bladder LCNECs have a rapid course and poor prognosis like the small cell variant. The role of surgery or chemotherapy in the treatment of LCNEC of the urinary bladder is not clear due to the rarity of the disease \[[@rjw179C1]\]. However, studies with pulmonary LCNEC show they respond well to standard chemotherapy regimens used for the small cell variants.

In our case, the follow-up period is 24 months following complete spontaneous remission of this very aggressive tumour and 3 years following surgical removal of the tumour. This suggests that although LCNEC is generally characterized by a very poor prognosis, it may behave very unpredictably.

CONCLUSION {#rjw179s4}
==========

LCNEC is a rare and aggressive disease. Although the overall prognosis is poor and most patient present with metastatic disease it can behave unpredictably. We believe this to be the first case of spontaneous remission of this disease. Because of the rarity of these tumours, there are no prospective trials done to evaluate the optimum treatment and our case is important as it adds to the current literature on the behaviour of this rare variant of bladder cancer.
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